Iterion Therapeutics

We are Initiating a Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive Non-Small Cell Lung Cancer (NSCLC).

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers

Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

Iterion is a proud sponsor of National Pediatric Cancer Foundation. We are excited to be part of this years Houston event - Fashion Funds the Cure! If you would like more information please see National Pediatric Cancer Foundation

Our very own Director of Translation Research
Ruolan Han, PhD

NUCLEAR β-CATENIN INHIBITOR - TBL1 - A Novel Target for Safe & Effective Blockade of the Nuclear β-catenin Signaling Pathway Ruolan Han, PhD, explains how targeting TBL1/TBLR1 enables specific silencing of oncogenic Wnt target gene expression without affecting other necessary cellular functions that are disrupted when targeting higher up the Wnt pathway.

We are excited to announce that we have entered into a strategic collaboration with Apollomics, the ideal partner to advance Tegavivint in the Greater China region.

https://www.globenewswire.com/news-release/2021/02/10/2173075/0/en/Apollomics-Inc-and-Iterion-Therapeutics-Announce-Exclusive-Collaboration-and-License-Agreement-to-Develop-and-Commercialize-Tegavivint-in-Greater-China.html